Log in

HSANZ statement on COVID-19-Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT)

14 Apr 2021 10:15 AM | Anonymous member (Administrator)

Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination

Updated 14 Apr 2021 10:30 AM

Leanne Berkahn and Steven Lane, on behalf of the HSANZ Council.

Statement regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination

The Haematology Society of Australia and New Zealand is aware of a number of case reports of Vaccine-induced Prothrombotic Immune Thrombocytopenia (VIPIT) following COVID-19 Vaccination. This is a dynamic topic and the clinical data are still emerging. HSANZ does not provide comment on specific cases, particularly without access to all of the information. However, we acknowledge that there is an important role in facilitating communication on this topic.

The following resources are available for clinicians and others seeking information on the topic. Note, these resources are linked for general interest and the content and recommendations are not specifically endorsed by HSANZ. Our webpage will be updated as more information/ resources come to hand.

https://www.tga.gov.au/media-release/specific-clotting-condition-reported-after-covid-19-vaccination

The Thrombosis Society of Australia and New Zealand have released some local guidelines. The following link provides information about the diagnosis and management of VIPIT and also a link to the referral form for testing of suspected cases. 

https://www.thanz.org.au/documents/item/577



CONTACT

Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114


FOLLOW US

Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.

Powered by Wild Apricot Membership Software